1. INTENDED USE

The second International Standard (IS) for Erythropoietin (EPO) in ampoules coded 88/574 has been widely used for the calibration of preparations of recombinant DNA-derived EPO by bioassay. Stocks of the 2nd IS are exhausted and the World Health Organization (WHO) Expert Committee on Biological Standardization (ECBS) has recognized (2010) the need for a replacement International Standard for EPO for the assignment of potency to therapeutic preparations of recombinant human EPO used in the treatment of anaemia.

A new preparation of recombinant EPO has been filled into ampoules (NIBSC Code 11/170) and has been characterized by in vivo bioassay in an international collaborative study with expert laboratories and was established as the 3rd International Standard at the 63rd meeting of the ECBS. This material replaces the 2nd IS.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

Each ampoule contains 1650 IU of EPO

4. CONTENTS

Country of origin of biological material: USA.

Each ampoule contains the residue after freeze-drying of 0.5 ml of a solution that contained:

- Recombinant human EPO: approximately 11 µg
- Human serum albumin: 0.2 % (w/v)
- Trehalose: 1.0 % (w/v)
- NaCl: 0.12 % (w/v)

5. STORAGE

Unopened ampoules should be stored at -20°C.

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Tap the ampoule gently to collect the material at the bottom (labeled) end. Ensure that the disposable ampoule safety breaker provided is pushed down on the stem of the ampoule and against the shoulder of the ampoule body. Hold the body of the ampoule in one hand and the disposable ampoule breaker covering the ampoule stem between the thumb and first finger of the other hand. Apply a bending force to open the ampoule at the coloured stress point, primarily using the hand holding the plastic collar.

Care should be taken to avoid cuts and projectile glass fragments that might enter the eyes, for example, by the use of suitable gloves and an eye shield. Take care that no material is lost from the ampoule and no glass falls into the ampoule. Within the ampoule is dry nitrogen gas at slightly less than atmospheric pressure. A new disposable ampoule breaker is provided with each DIN ampoule.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.

For practical purposes, each ampoule contains the same quantity of recombinant human EPO. The entire content of each ampoule should be completely dissolved in an accurately measured amount of buffer solution. The use of water to reconstitute ampoule contents is not recommended. The material has not been sterilized and the ampoules contain no bacteriostat.

COLLABORATIVE STUDY

The preparation was evaluated in a collaborative study in which fifteen laboratories in seven countries took part, organized with the following aims:

1) To calibrate the candidate preparation, 11/170 relative to the 2nd IS (88/574) for EPO by in vivo bioassays.

2) To determine the stability of the candidate preparation 11/170 by comparison with ampoules stored at elevated temperatures as part of an accelerated degradation stability study.

The geometric mean potency for the candidate standard was 1648 IU per ampoule (n =15; 95% confidence limits 1562 - 1738; GCV 10.1%)

The candidate preparation 11/170 is sufficiently stable to serve as an International Standard. Analysis of the thermally accelerated degradation samples in this study demonstrated no detectable loss of potency at these elevated temperatures. This suggests that 11/170 is likely to be highly stable under long term storage at -20°C.

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label. It is the policy of WHO not to assign an expiry date to their international reference materials. They remain valid with the assigned potency and status until withdrawn or amended.

In addition, once reconstituted, diluted or aliquotted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

Further information can be obtained from the report of the collaborative study which is available from the WHO website: http://www.who.int/biologicals/en/

10. ACKNOWLEDGEMENTS

We gratefully acknowledge the important contributions of all the participants and the manufacturer of the therapeutic EPO for the kind donation of material.

11. FURTHER INFORMATION

Further information can be obtained as follows:

This material: enquiries@nibsc.org

WHO Biological Standards:
http://www.who.int/biologicals/en/

JCTLM Higher order reference materials:
12. CUSTOMER FEEDBACK  
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION  
In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET  
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance:</td>
<td>Freeze dried powder</td>
</tr>
<tr>
<td>Corrosive:</td>
<td>No</td>
</tr>
<tr>
<td>Stable:</td>
<td>Yes</td>
</tr>
<tr>
<td>Oxidising:</td>
<td>No</td>
</tr>
<tr>
<td>Hygroscopic:</td>
<td>Yes</td>
</tr>
<tr>
<td>Irritant:</td>
<td>No</td>
</tr>
<tr>
<td>Flammable:</td>
<td>No</td>
</tr>
<tr>
<td>Handling: See caution, Section 2</td>
<td></td>
</tr>
<tr>
<td>Other (specify):</td>
<td>Contains material of human origin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Toxicological properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of inhalation:</td>
<td>Not established, avoid inhalation</td>
</tr>
<tr>
<td>Effects of ingestion:</td>
<td>Not established, avoid ingestion</td>
</tr>
<tr>
<td>Effects of skin absorption:</td>
<td>Not established, avoid contact with skin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Suggested First Aid</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation:</td>
<td>Seek medical advice</td>
</tr>
<tr>
<td>Ingestion:</td>
<td>Seek medical advice</td>
</tr>
<tr>
<td>Contact with eyes:</td>
<td>Wash with copious amounts of water. Seek medical advice</td>
</tr>
<tr>
<td>Contact with skin:</td>
<td>Wash thoroughly with water.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action on Spillage and Method of Disposal</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.</td>
<td></td>
</tr>
</tbody>
</table>

15. LIABILITY AND LOSS  
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY  
Country of origin for customs purposes*: United Kingdom  
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.  
Net weight: 6mg  
Toxicity Statement: Non-toxic  
Veterinary certificate or other statement if applicable. Attached: No

17. CERTIFICATE OF ANALYSIS  
NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter Biol efstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.